BiomX Inc. (NYSEAMERICAN:PHGE – Get Free Report) was the recipient of a large growth in short interest in the month of August. As of August 31st, there was short interest totaling 623,734 shares, a growth of 83.3% from the August 15th total of 340,328 shares. Approximately 2.3% of the company’s shares are short sold. Based on an average trading volume of 1,058,843 shares, the short-interest ratio is currently 0.6 days.
BiomX Stock Performance
BiomX has a twelve month low of $1.19 and a twelve month high of $122.93. The company has a debt-to-equity ratio of 0.02, a current ratio of 0.24 and a quick ratio of 0.24. The company has a fifty day simple moving average of $1.74 and a two-hundred day simple moving average of $15.01. The firm has a market cap of $4.94 million, a P/E ratio of -0.58 and a beta of 1.33.
BiomX (NYSEAMERICAN:PHGE – Get Free Report) last released its quarterly earnings results on Wednesday, August 19th. The company reported ($3.70) EPS for the quarter. The firm had revenue of $0.33 million for the quarter. As a group, equities research analysts forecast that BiomX will post -58.5 earnings per share for the current fiscal year.
About BiomX
BiomX Inc is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.
The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis.
See Also
- Five stocks we like better than BiomX
- Micron’s AI Memory Boom Could Send Shares 100% Higher
- Apple Stock Surges After Its Biggest Product Launch in Years—Can It Last?
- The Ultimate Cyber Shield: CrowdStrike Rises Past $235
- Palantir Just Told Wall Street Where AI Infrastructure Is Headed
Receive News & Ratings for BiomX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiomX and related companies with MarketBeat.com's FREE daily email newsletter.
